Back to Market返回行情

ANGO AngioDynamics, Inc.

USHealthcare
$12.79-1.01%ClosedMarket Cap: $528.5M

As of 2026-07-10 16:00

Why ANGO matters now

AngioDynamics, Inc. (ANGO) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.79 with -1.01% on the session and $528.5M in market capitalization; recent performance reads 1-month +6.21% and YTD -5.37%.

The latest financial table shown here is Q3 2026, with revenue of $78.4M, net income of $-8.1M, and EPS of $-0.19. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.3%.

The latest indexable market news headline is "AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026" from Business Wire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $16.00. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

2.92

P/S

1.60

EV/EBITDA

-85.29

DCF Value

$2.50

FCF Yield

0.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

53.5%

Operating Margin

-8.1%

Net Margin

-10.0%

ROE

-17.6%

ROA

-12.0%

ROIC

-13.0%

Financials

PeriodRevenueNet IncomeEPS
Q3 2026$78.4M$-8.1M$-0.19
Q2 2026$79.4M$-6.3M$-0.15
Q1 2026$75.7M$-10.9M$-0.26
Q4 2025$80.2M$-6.0M$-0.15

Analyst Ratings

Consensus

Buy

Target (Consensus)

$16.50

Target (Median)

$16.00

Target Range

$12.00 - $22.00

Strong Buy: 0Buy: 4Hold: 0Sell: 0Strong Sell: 0
Canaccord GenuityBuy
2026-04-06
Canaccord GenuityBuy
2025-10-03
Canaccord GenuityBuy
2025-07-16
HC Wainwright & Co.Buy
2025-07-16

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

US

Exchange

Beta

0.36

AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.